Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14855774 | 1.00 | HRH3 (0.38) | HRH3SIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL14856258 | 1.00 | HRH3 (0.38) | HRH3SIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL5998295 | 1.00 | HRH3 (0.38) | HRH3SIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL14915000 | 1.00 | HRH3 (0.38) | HRH3SIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL15047433 | 1.00 | HRH3 (0.38) | HRH3SIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL5995166 | 1.00 | HRH3 (0.38) | HRH3SIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL5971686 | 1.00 | HRH3 (0.38) | HRH3SIGMAR1MEN1ALDH1A1KMT2A | |
| SCHEMBL26446019 | 0.88 | KDM4E (0.41) | HRH3MEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL26433911 | 0.88 | KDM4E (0.41) | HRH3MEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL26433881 | 0.88 | KDM4E (0.41) | HRH3MEN1ALDH1A1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3303326-B1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-12-16 | — | — | EP | disclosed |
| EP-3303326-B1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-12-16 | — | — | EP | disclosed |
| CN-107531722-B | Heterocyclic estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2020-07-17 | — | — | CN | disclosed |
| US-10053451-B2 | Heterocyclic estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-9868704-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868704-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868704-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| EP-3205648-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Seragon Pharmaceuticals, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| WO-2011159769-A2 | INDANE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011156518-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011156518-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| EP-1501819-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2010-09-15 | — | — | EP | disclosed |
| EP-1501819-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2010-09-15 | — | — | EP | disclosed |
| US-7138426-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1501819-A4 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050234245-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-10-20 | — | — | US | disclosed |
| EP-1501819-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091239-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234245-A1 | Estrogen receptor modulators | ESRRB, ESR2, GPER1 | HRH3 2588/4885SIGMAR1 569/4885MEN1 1646/4885 |
| US-10053451-B2 | Heterocyclic estrogen receptor modulators and uses thereof | ESR2, GPER1, ESRRG | HRH3 1262/4885SIGMAR1 254/4885MEN1 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.